GT Biopharma, Inc. (GTBP) vs SeaStar Medical Holding Corporation (ICU)

GT Biopharma, Inc. and SeaStar Medical Holding Corporation are both Biotechnology companies. GT Biopharma, Inc. and SeaStar Medical Holding Corporation are of similar size ($10.2M and $9.4M). SeaStar Medical Holding Corporation has negative trailing earnings, so its P/E is not meaningful; GT Biopharma, Inc. trades at 0.8×. SeaStar Medical Holding Corporation grew revenue faster over the last twelve months: 123.6% against −76.2%. GT Biopharma, Inc. has the higher net margin (0.00% vs −795.5%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, SeaStar Medical Holding Corporation leads on 8 and GT Biopharma, Inc. on 7.

Valuation

Metric GTBP ICU Biotechnology median
P/E 0.76 n/m 10.60
P/S 114.39 4.55 9.40
P/B 1.92 1.82 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 475.21 1.99 9.02
Earnings yield 130.83% (204.71%) (32.88%)
Free cash flow yield (207.77%) (175.54%) (23.13%)

Profitability

Metric GTBP ICU Biotechnology median
Gross margin 41.67% 92.64% 68.51%
Operating margin 0.00% (816.75%) 0.00%
Net margin 0.00% (795.50%) 0.00%
Free cash flow margin 0.00% (799.36%) 0.00%
Return on equity 102.03% (356.87%) (51.96%)
Return on assets (176.27%) (160.02%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric GTBP ICU Biotechnology median
Revenue growth (TTM) (76.19%) 123.63% 6.76%
EPS growth (last fiscal year) 3.75% 91.16% 29.88%
Revenue growth, 5-year CAGR 19.67% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric GTBP ICU Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 2.61 1.89 4.97
Net debt to EBITDA 0.56 0.99 1.01

Dividend

Metric GTBP ICU Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric GTBP ICU Biotechnology median
Market cap 9.36m 10.20m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack